Adoption of MRL for Ectosan Vet in Norway

15 July 2021

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

Adoption of MRL for Ectosanâ Vet in Norway

Benchmark Holdings, the aquaculture biotechnology company, is pleased to announce that the MRL (Maximum Residue Limit) for Ectosanâ Vet has been adopted into the Agreement of the European Economic Area (the EEA Agreement); and today, has entered into Norwegian legislation completing the regulatory steps required for the commercialisation of Ectosanâ Vet and CleanTreatâ in Norway.

Trond Williksen, CEO, commented:

"With the granting of the Marketing Authorisation on 2nd July, the MRL ratified by the European Commission and now in Norwegian legislation, we have completed the regulatory steps required to begin the commercialisation of Ectosanâ Vet and CleanTreatâ in Norway."  

"We are excited to bring this much needed solution to the salmon industry, driving sustainability through improved animal welfare and yield while protecting the environment."

Enquiries